x

Search for a clinical trial

* (*) mandatory field

10 Result(s)

Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial
; Funded by an IRDiRC member = ; Member of a ERN =

National clinical trial(s)

UNITED KINGDOM

Greater London
LONDON

CMT-TRAUK: Randomised double blind placebo controlled trial of long term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (Phase III) (Completed)
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

UNITED KINGDOM

Greater London
LONDON

PADIMAC: Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT - UK
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

UNITED KINGDOM

Greater London
LONDON

Bortezomib Consolidation Trial: A Phase II study of bortezomib consolidation after high dose therapy and autologous stem cell transplantation for multiple myeloma - UK
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

UNITED KINGDOM

Greater London
LONDON

Ongoing trial
An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies-GB
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

UNITED KINGDOM

Greater London
LONDON

Ongoing trial
Funded by an IRDiRC memberPhase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM) - GB
UCL Institute of Neurology, University College London,
Clinical Neurosciences

UNITED KINGDOM

Greater London
LONDON

Recruiting trial
Ongoing trial
COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
University College London Hospitals NHS Foundation Trust
Cancer Division